MyFinsight
Home
Blog
About
BriaCell Therapeutics Corp. (BCTXW)
BriaCell Therapeutics Corp. (BCTXW)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$7,779,796
Unit: Dollar
Positive Cash Flow Breakdown
Decrease in amounts receivable a...
Increase in accrued expenses and...
Change in fair value of the warr...
Others
Negative Cash Flow Breakdown
Net loss for the period
Decrease in accounts payable
Financial expenses, net
Equity investment in bc therapeu...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2025-10-31
2025-07-31
Net loss for the period
-8,278,328
-26,556,140
Amortization
3,818
15,271
Financial expenses, net
89,487
56,473
Depreciation
22,839
91,356
Share-based compensation
294,686
776,879
Equity losses
-44,830
-224,212
Change in fair value of the warrant liability
69,201
-758,364
Decrease (increase) in amounts receivable
-
-733,629
Decrease in prepaid expenses
-
-492,279
Decrease in amounts receivable and prepaid expenses
887,860
-
Decrease in accounts payable
-1,154,788
-3,887,078
Increase in accrued expenses and other payables
494,573
753,909
Total cash flow from operating activities
-7,704,796
-28,170,520
Purchase of short-term investments, net
-
7,316,000
Equity investment in bc therapeutics
75,000
330,000
Total cash flow from investing activities
-75,000
-7,646,000
Proceeds from exercise of warrants
-
821,015
Proceeds from issuance of shares, net of issuance costs
-
44,627,224
Net cash provided by financing activities
-
45,448,239
Increase (decrease) in cash and cash equivalents
-7,779,796
9,631,719
Cash and cash equivalents at beginning of period
10,493,808
862,089
Cash and cash equivalents at end of period
2,714,012
10,493,808
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Increase (decrease) in
cash and cash...
-$7,779,796
Decrease in amounts
receivable and prepaid...
$887,860
Increase in accrued
expenses and other...
$494,573
Share-based compensation
$294,686
Change in fair value of
the warrant...
$69,201
Equity losses
-$44,830
Depreciation
$22,839
Amortization
$3,818
Total cash flow from
operating activities
-$7,704,796
Total cash flow from
investing activities
-$75,000
Canceled cashflow
$1,817,807
Net loss for the
period
-$8,278,328
Equity investment in bc
therapeutics
$75,000
Decrease in accounts
payable
-$1,154,788
Financial expenses, net
$89,487
Buy us a coffee